The case for & against
Bull & Bear analysis
Journey Medical, Inc. (NASDAQ: DERM) operates in the dermatology sector, specifically focusing on innovative treatments for skin conditions, with its flagship product being MROSI, an oral treatment for rosacea. The company is carving a niche in a highly competitive market, where it seeks to disrupt established norms with effective therapeutic solutions for chronic skin conditions. Journey Medical's strategic positioning is enhanced by its ongoing development of other dermatological therapies to supplement its existing portfolio, aimed at addressing significant unmet medical needs in the industry.
Bull says
- ↑MROSI net sales hit $14.7M in first nine months; total revenues +11% YoY.
- ↑Gross margin expanded to 66.2% from 62.8% YoY, driven by favorable product mix.
- ↑Annualized MROSI prescription run rate exceeds 126k across 3,500 prescribers.
- ↑GPO contracts cover ~100M insured lives; third major GPO deal due Q2.
- ↑High growth potential and strong balance-sheet quality support stock stability.
- ↑Clinical superiority may capture share in $1B+ rosacea treatment market.
Bear says
- ↓Net loss of $11.4M in 2025 (vs. $14.7M prior year); EBITDA still negative.
- ↓Accutane and legacy products face generic competition, pressuring revenue base.
- ↓Reimbursement lag (2–3 quarters per GPO) could slow script coverage.
- ↓Weak profitability and negative earnings yield raise returns concerns.
- ↓High short interest signals bearish sentiment risking downward share pressure.
- ↓Scaling challenges and no dividend weigh on long-term investor confidence.
Investment themes with DERM
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Total revenues for the year were $61.9 million, representing a 10% increase compared to $56.1 million for 2024. The increase reflects incremental net product revenue related to the successful U.S. commercial launch of Ambrosie.
- Gross margin for 2025 was 66.2% compared to 62.8% in 2024. The improvement reflects a favorable product mix with higher margin contributions from Enrose EQ Brexa, along with lower overall inventory period costs.
- On a non-GAAP basis, both EBITDA and adjusted EBITDA improved year over year. EBITDA improved by $5.2 million, narrowing from a loss of $9.2 million in 2024 to a loss of $4 million in 2025. Adjusted EBITDA was a positive $2.9 million for the full year 2025 compared to $800,000 in 2024, reflecting further progress towards our goal of sustainable profitability.
Bear points
- SG&A expenses totaled $44.4 million for 2025, up approximately 10% from $40.2 million to 2024. This increase reflects additional operating activities to support the launch and continued expansion of EMROSI.
- We reported a gap net loss of $11.4 million, with 47 cents per share basic and diluted for 2025, compared to a gap net loss of $14.7 million, or 72 cents per share, in 2024.
- demand lag, revenue lag.